Key Takeaways Retatrutide (LY3437943) is an investigational weight loss medication developed by Eli Lilly Triple-agonist mechanism: First drug to activate GLP-1, GIP, and glucagon receptors simultaneously Phase 2 results: Up to 24.2% weight loss at 48 weeks (approximately 58 lbs for a 240-lb person) Not FDA-approved: Currently in Phase 3 clinical trials, expected approval in 20272028 How it differs: Outperforms semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in weight loss trials Access now: Clinical trials (free), compounding pharmacies, or research peptide vendors What Is Retatrutide
Taking too little may not significantly support cellular glutathione levels, while unnecessarily high doses may offer diminishing returns, as the body can only utilize a limited amount at a time
Gutirrez RMP, Gmez JT, Jernimo FFM, Paredes-Carrera SP, Snchez-Ochoa JC (2023) Effects of selenium nanoparticles using potential natural compounds naringenin and baicalin for diabetes
Pyridoxine plays a significant role in the proper functioning of the nervous, immune, and gastrointestinal systems
Patients typically begin at a lower dose and increase gradually every four weeks to minimize gastrointestinal side effects and maximize tolerability
Whats the cause
